Psychedelic Research and Access in
Malta
Malta has a small visible psychedelic footprint in Blossom, with one linked event and no linked country-specific psychedelic clinical trials. The page is therefore best read as a light regulatory and ecosystem note rather than a developed clinical research profile.
Data updated
Key Insights
A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inMalta.
- 1
Blossom currently links Malta to one psychedelic event and no country-linked psychedelic clinical trials.
- 2
Malta has medicines and ethics-review infrastructure that could support authorised research, but no clear public psychedelic research footprint is visible in the lightweight review.
- 3
Classic psychedelics should be framed as controlled rather than generally available for treatment.
- 4
Esketamine-related access should be checked separately because EU authorisation does not automatically establish local reimbursement or routine public provision.
- 5
Future updates should watch Maltese Medicines Authority, ethics-review, CTIS, and local clinical-service sources.
Research and Access Snapshot
Blossom currently tracks no country-linked psychedelic clinical trials for Malta, but the page does include 3 stakeholders and 1 event.
Blossom has not linked country-level trial records yet. Treat this as a coverage gap, not proof that no local policy discussion, care, or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 3
- Events
- 1
None marked active
No linked trials
Linked organisations
Linked events
Top Compounds
Linked country trials do not show a leading compound yet.
Top Study Topics
Linked country trials do not show a leading study topic yet.
Medical Access
Malta follows EU/UN psychotropic scheduling for classic psychedelics (psilocybin, MDMA, DMT, mescaline etc.), meaning they are criminally controlled and only available for authorised research or exceptional clinical/regulatory pathways. Esketamine (Spravato) is authorised across the EU and therefore may be placed on the Maltese market, but routine public reimbursement and widespread public-sector provision for psychedelic therapies (including ketamine infusions for TRD) remain limited or handled on a case-by-case / private-clinic basis.
Regulatory Status
Malta appears to sit within a conventional EU/UN controlled-substances and medicines-authorisation framework. Classic psychedelics should be treated as controlled substances unless an authorised research, exceptional-use, or other lawful pathway is verified. EU centralised authorisation may be relevant for products such as esketamine, but Maltese availability, reimbursement, and public-sector provision should not be assumed without product- and setting-specific confirmation.
Country Details
- Region
- Europe
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access
Malta follows EU/UN psychotropic scheduling for classic psychedelics (psilocybin, MDMA, DMT, mescaline etc.), meaning they are criminally controlled and only available for authorised research or exceptional clinical/regulatory pathways. Esketamine (Spravato) is authorised across the EU and therefore...
Open access guide →Pro Scorecard
Country Scorecard
Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Malta.
Open scorecard →Psychedelic Stakeholders in Malta
Organisations, sponsors, clinics, and research groups connected to psychedelic science in Malta.
Research Events in Malta
Conferences, trainings, and research gatherings connected to the country report.